Abstract:Background: Endocrine-disrupting chemicals (EDCs) often exhibit nonmonotonic dose-response (NMDR) relationships, posing significant challenges to health risk assessment and regulations. Several molecular mechanisms operating locally in cells have been proposed, including opposing actions via different receptors, mixed-ligand heterodimer formation, and receptor downregulation. Systemic negative feedback regulation of hormone homeostasis, which is a common feature of many endocrine systems, has also been invoked as a mechanism; however, whether and how exactly such global feedback structure may underpin NMDRs is poorly understood. Objectives: We hypothesize that an EDC may compete with the endogenous hormone for receptors (i) at the central site to interfere with the feedback regulation thus altering the physiological hormone level, and (ii) at the peripheral site to disrupt the hormone action; this dual-action may oppose each other, producing nonmonotonic endocrine effects. The objective here is to explore - through computational modeling - how NMDRs may arise through this potential mechanism and the relevant biological variabilities that enable susceptibility to nonmonotonic effects. Methods: We constructed a dynamical model of a generic hypothalamic-pituitary-endocrine (HPE) axis with negative feedback regulation between a pituitary hormone and a terminal effector hormone (EH). The effects of model parameters, including receptor binding affinities and efficacies, on NMDR were examined for EDC agonists and antagonists. Monte Carlo human population simulations were then conducted to systemically explore biological parameter conditions that engender NMDR. Results: When an EDC interferes sufficiently with the central feedback action of EH, the net endocrine effect at the peripheral target site can be opposite to what is expected of an agonist or antagonist at low concentrations. J/U or Bell-shaped NMDRs arise when the EDC has differential binding affinities and/or efficacies, relative to EH, for the peripheral and central receptors. Quantitative relationships between these biological variabilities and associated distributions were discovered, which can distinguish J/U and Bell-shaped NMDRs from monotonic responses. Conclusions: The ubiquitous negative feedback regulation in endocrine systems can act as a universal mechanism for counterintuitive and nonmonotonic effects of EDCs. Depending on key receptor kinetic and signaling properties of EDCs and endogenous hormones, some individuals may be more susceptible to these complex endocrine effects.

Opinion on the impact of non‐monotonic dose responses on EFSA′s human health risk assessments

Review of dose setting for the extended one-generation reproductive toxicity studies (OECD TG 443): Considerations on ECHA's dose level selection recommendations

Evaluation of Exposure Concentrations Used in Assessing Manufactured Nanomaterial Environmental Hazards: Are They Relevant?

Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment

Review of Current and “omics” Methods for Assessing the Toxicity (genotoxicity, Teratogenicity and Nephrotoxicity) of Herbal Medicines and Mushrooms

New approach methodologies in human regulatory toxicology - Not if, but how and when!

Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!

Updated reasoned opinion on the toxicological properties and maximum residue levels (MRLs) for the benzimidazole substances carbendazim and thiophanate-methyl

Interference with Systemic Negative Feedback Regulation as a Potential Mechanism for Nonmonotonic Dose-Responses of Endocrine-Disrupting Chemicals

Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals

Opportunities and Challenges Related to Saturation of Toxicokinetic Processes: Implications for Risk Assessment

An ecotoxicological view on neurotoxicity assessment

Use of dislodgeable foliar residue studies for the evaluation of isomerization potential of active substances for non-dietary risk assessment

Considerations for the development of guidance on dose level selection for developmental and reproductive toxicity studies

Genotoxicity testing approaches for the safety assessment of substances used in food contact materials prior to their authorization in the European Union

The Use of Effect Biomarkers in Chemical Mixtures Risk Assessment – are they Still Important?

Resource and animal use implications of the proposed REACH information requirements for endocrine disruptor assessment

Recent advances and current challenges of new approach methodologies in developmental and adult neurotoxicity testing

Benchmark dose (BMD) modeling: current practice, issues, and challenges

Comparative case study on NAMs: towards enhancing specific target organ toxicity analysis

New approach methodologies to confirm developmental toxicity of pharmaceuticals based on weight of evidence